NCT03197389View on ClinicalTrials.gov

Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 18, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Breast CancerTriple Negative Breast CancerHormone Receptor Negative Neoplasm
Interventions
DRUG

Pembrolizumab

Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.

Trial Locations (1)

3000

University Hospitals Leuven, Leuven

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT03197389 - Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer. | Biotech Hunter | Biotech Hunter